Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/GAPDH_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/GAPDH_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/GAPDH_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/GAPDH_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/GAPDH_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GAPDH_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/GAPDH_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GAPDH_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/GAPDH_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GAPDH_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/GAPDH_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GAPDH_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GAPDH_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0045861113 | Thyroid | PTC | negative regulation of proteolysis | 136/5968 | 351/18723 | 3.54e-03 | 1.71e-02 | 136 |
GO:003434110 | Thyroid | PTC | response to interferon-gamma | 59/5968 | 141/18723 | 7.88e-03 | 3.33e-02 | 59 |
GO:00713468 | Thyroid | PTC | cellular response to interferon-gamma | 50/5968 | 118/18723 | 1.04e-02 | 4.19e-02 | 50 |
GO:0046034210 | Thyroid | goiters | ATP metabolic process | 46/497 | 277/18723 | 1.19e-23 | 1.65e-20 | 46 |
GO:000609128 | Thyroid | goiters | generation of precursor metabolites and energy | 48/497 | 490/18723 | 5.54e-15 | 1.53e-12 | 48 |
GO:0006417210 | Thyroid | goiters | regulation of translation | 35/497 | 468/18723 | 3.94e-08 | 3.71e-06 | 35 |
GO:0050821210 | Thyroid | goiters | protein stabilization | 21/497 | 191/18723 | 4.03e-08 | 3.71e-06 | 21 |
GO:0031647210 | Thyroid | goiters | regulation of protein stability | 26/497 | 298/18723 | 1.18e-07 | 9.61e-06 | 26 |
GO:0052547210 | Thyroid | goiters | regulation of peptidase activity | 33/497 | 461/18723 | 2.68e-07 | 1.98e-05 | 33 |
GO:0052548210 | Thyroid | goiters | regulation of endopeptidase activity | 31/497 | 432/18723 | 5.88e-07 | 3.75e-05 | 31 |
GO:0045861210 | Thyroid | goiters | negative regulation of proteolysis | 24/497 | 351/18723 | 2.46e-05 | 9.17e-04 | 24 |
GO:0044403210 | Thyroid | goiters | biological process involved in symbiotic interaction | 21/497 | 290/18723 | 3.42e-05 | 1.23e-03 | 21 |
GO:0009150113 | Thyroid | goiters | purine ribonucleotide metabolic process | 22/497 | 368/18723 | 3.62e-04 | 9.15e-03 | 22 |
GO:0019693113 | Thyroid | goiters | ribose phosphate metabolic process | 23/497 | 396/18723 | 4.03e-04 | 9.95e-03 | 23 |
GO:0009259113 | Thyroid | goiters | ribonucleotide metabolic process | 22/497 | 385/18723 | 6.65e-04 | 1.55e-02 | 22 |
GO:0001819110 | Thyroid | goiters | positive regulation of cytokine production | 25/497 | 467/18723 | 7.60e-04 | 1.71e-02 | 25 |
GO:0072521113 | Thyroid | goiters | purine-containing compound metabolic process | 23/497 | 416/18723 | 7.94e-04 | 1.74e-02 | 23 |
GO:001050623 | Thyroid | goiters | regulation of autophagy | 19/497 | 317/18723 | 8.67e-04 | 1.87e-02 | 19 |
GO:0006163113 | Thyroid | goiters | purine nucleotide metabolic process | 22/497 | 396/18723 | 9.62e-04 | 2.01e-02 | 22 |
GO:003164734 | Thyroid | ATC | regulation of protein stability | 177/6293 | 298/18723 | 4.08e-20 | 6.46e-18 | 177 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GAPDH | SNV | Missense_Mutation | | c.658N>C | p.Val220Leu | p.V220L | P04406 | protein_coding | deleterious_low_confidence(0.01) | benign(0.409) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
GAPDH | SNV | Missense_Mutation | novel | c.550A>G | p.Thr184Ala | p.T184A | P04406 | protein_coding | deleterious_low_confidence(0) | benign(0.1) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
GAPDH | insertion | Frame_Shift_Ins | novel | c.536_537insT | p.Ala180CysfsTer19 | p.A180Cfs*19 | P04406 | protein_coding | | | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GAPDH | insertion | In_Frame_Ins | novel | c.538_539insCCCTTCTCCCCATTCCGTCTT | p.Ala180_Ile181insLeuLeuProIleProSerSer | p.A180_I181insLLPIPSS | P04406 | protein_coding | | | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GAPDH | insertion | Frame_Shift_Ins | novel | c.322_323insGGTGGGCTTGCCCTGTCCAGTTAATTTCTGAC | p.Ala108GlyfsTer39 | p.A108Gfs*39 | P04406 | protein_coding | | | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GAPDH | SNV | Missense_Mutation | | c.274N>A | p.Ala92Thr | p.A92T | P04406 | protein_coding | deleterious_low_confidence(0.03) | benign(0.07) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GAPDH | SNV | Missense_Mutation | | c.599N>T | p.Arg200Leu | p.R200L | P04406 | protein_coding | tolerated_low_confidence(0.06) | benign(0.068) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
GAPDH | SNV | Missense_Mutation | | c.306C>G | p.Phe102Leu | p.F102L | P04406 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.805) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
GAPDH | SNV | Missense_Mutation | novel | c.887A>G | p.Asp296Gly | p.D296G | P04406 | protein_coding | deleterious_low_confidence(0.01) | benign(0.423) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GAPDH | SNV | Missense_Mutation | | c.266N>G | p.Asp89Gly | p.D89G | P04406 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.615) | TCGA-AP-A0LP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Hormone Therapy | megace | SD |